Which cognitive biases were evident in Mylan N.V.'s failure?

5 bias patterns are documented in this case, led by Anchoring Bias. The full set: Anchoring Bias, Loss Aversion, Status Quo Bias, Hindsight Bias, Framing Effect. Each is mapped to Decision Intel's 22-bias R²F taxonomy with stable IDs and academic citations.

Did these cognitive biases cause Mylan N.V.'s failure?

Decision Intel identifies reasoning-risk indicators correlated with poor outcomes — it does not claim to establish causation. That honesty is the procurement weapon: a CSO can defend a score that names the risk indicators a committee should pressure-test, not one that pretends to prove the cause. Anchoring Bias and the other documented patterns were detectable in the reasoning before the outcome was known; whether they caused it is a question no audit can settle — too many other factors (market, timing, execution) are in play. A reasoning audit names the risk indicators a committee should pressure-test, not a verdict it should accept.

What is Decision Intel's reasoning audit?

Decision Intel runs a Recognition-Rigor Framework (R²F) audit on strategic memos, detecting cognitive biases from a 22-bias canonical taxonomy and producing a Decision Quality Index (DQI) score. The audit produces a hashed, tamper-evident Decision Provenance Record (DPR) suitable for audit-committee review.

All case studies

FailureHealthcare2016

Mylan N.V.

Mylan EpiPen Pricing Scandal

Estimated impact: $465M DOJ settlement; market share loss to generics

F33

Decision Quality Index (simulated)

Critical · 5 biases detected, 1 toxic combinations

Mylan raised the price of the EpiPen from $57 to $609 (a 400%+ increase) over eight years while CEO Heather Bresch's compensation grew to $19M. The pricing exploited the product's life-saving monopoly status and lack of generic alternatives.

Decision context

Whether to continue systematic annual price increases on a life-saving product with no therapeutic alternatives, and whether the pricing strategy was sustainable politically and commercially.

Deep hindsight-stripped analysis coming soon. This case is part of our ongoing backfill to reconstruct what was flaggable in the record at decision time. The summary and bias profile below are drawn from primary sources.

Decision anatomy

Monetary stakes

Very high

Dissent suppressed

Yes

Time pressure

None

Unanimous consensus

Yes

Decision participants

Dissent encouraged

External advisors

Iterative process

Red = risk factor present · Green = protective factor present

Biases present in the decision

★Anchoring Bias

critical

Loss Aversion

medium

Status Quo Bias

medium

Hindsight Bias

medium

Framing Effect

medium

★ Primary driver · Severity estimated from bias type and decision outcome

3D Decision Knowledge Graph

Mylan N.V. · 5 biases, 1 toxic combination

Drag to rotate · Scroll to zoom · Click to explore

Decision

Critical

High

Medium

Toxic

Bias Intensity Profile

Severity × confidence across 5 detected biases

Toxic combinations

!Status Quo Lock

Loss aversion combined with status quo bias makes even clearly beneficial change feel impossible.

The curated library this case sits in

Across all 155 curated case studies in our library, by documented outcome:

123

documented failures

partial / mixed

documented successes

The library is curated toward documented failures, so this split describes the library, not the base rate of deals. The case above is one row in it.

■ Failure■ Partial■ Success

Lessons learned

Anchoring to annual price increase percentages rather than absolute cost to patients created a trajectory that became politically unsustainable
Loss aversion: once high prices were embedded in revenue forecasts, any reduction felt like a loss rather than normalization
Hindsight bias: the pricing was publicly available for years before it became a political issue — the risk was always present

Source: U.S. Senate Special Committee on Aging hearing (2016); DOJ settlement (2017) (News Investigation)

Pilot slots available

These patterns were flaggable in Mylan N.V.'s own record — before the outcome.

See the full reasoning audit we ran — no login, no card. Then run the same audit on a deal you have already closed.

See a live audit · no login Audit a deal of your own

Or leave your email, we'll run the audit on a deal of your choosing and send the readout within a business day.

Audit your own decision

Workflows that fire on decisions like Mylan N.V.’s

The same Recognition-Rigor Framework that documents this case audits memos in the same shape — before the outcome forces the lesson.

For CSOs and Heads of Strategic Planning

Strategic memo audit

Audit a strategic memo for cognitive bias and forecast errors before the board sees it.

Audit a strategic memo

For any high-stakes decision, before commitment

Decision pre-mortem

Run a structured pre-mortem before the decision is final — surface failure modes the room cannot see from the inside.

Run a pre-mortem

For CSOs and CEOs presenting to a board

Board deck pre-presentation audit

Audit a board deck before the presentation — predict the toughest questions the room will ask.

Audit your board deck

See the full audit-tool surface.

Related cases in Healthcare

Failure2021

Credit Suisse

Credit Suisse Archegos Capital Losses

Catastrophic failure2000

Blockbuster

Blockbuster Rejection of Netflix Partnership

Success2008

Spotify

Spotify Freemium Model Against Piracy

Catastrophic failure2023

Silicon Valley Bank

Silicon Valley Bank Collapse

All case studies

FailureHealthcare2016

Mylan N.V.

Mylan EpiPen Pricing Scandal

Estimated impact: $465M DOJ settlement; market share loss to generics

F33

Decision Quality Index (simulated)

Critical · 5 biases detected, 1 toxic combinations

Decision context

Whether to continue systematic annual price increases on a life-saving product with no therapeutic alternatives, and whether the pricing strategy was sustainable politically and commercially.

Decision anatomy

Monetary stakes

Very high

Dissent suppressed

Yes

Time pressure

None

Unanimous consensus

Yes

Decision participants

Dissent encouraged

External advisors

Iterative process

Red = risk factor present · Green = protective factor present

Biases present in the decision

★Anchoring Bias

critical

Loss Aversion

medium

Status Quo Bias

medium

Hindsight Bias

medium

Framing Effect

medium

★ Primary driver · Severity estimated from bias type and decision outcome

3D Decision Knowledge Graph

Mylan N.V. · 5 biases, 1 toxic combination

Drag to rotate · Scroll to zoom · Click to explore

Decision

Critical

High

Medium

Toxic

Bias Intensity Profile

Severity × confidence across 5 detected biases

Toxic combinations

!Status Quo Lock

Loss aversion combined with status quo bias makes even clearly beneficial change feel impossible.

The curated library this case sits in

Across all 155 curated case studies in our library, by documented outcome:

123

documented failures

partial / mixed

documented successes

The library is curated toward documented failures, so this split describes the library, not the base rate of deals. The case above is one row in it.

■ Failure■ Partial■ Success

Lessons learned

Anchoring to annual price increase percentages rather than absolute cost to patients created a trajectory that became politically unsustainable
Loss aversion: once high prices were embedded in revenue forecasts, any reduction felt like a loss rather than normalization
Hindsight bias: the pricing was publicly available for years before it became a political issue — the risk was always present

Source: U.S. Senate Special Committee on Aging hearing (2016); DOJ settlement (2017) (News Investigation)

Pilot slots available